{"id":"W3163488215","doi":"10.1136/rmdopen-2021-001679","title":"Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials","year":2021,"lang":"en","type":"article","venue":"RMD Open","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Infection and Immunity","funders":"Janssen Research and Development; Celgene; Biogen; Gilead Sciences; Asia Pacific League of Associations for Rheumatology; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Ustekinumab; Arthritis; Immunology; Interleukin 23; Interleukin 17; Secukinumab; Internal medicine; C-reactive protein; Psoriasis; Placebo; Acute-phase protein; Cytokine; Tumor necrosis factor alpha; Gastroenterology; Inflammation; Adalimumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001392548,0.0004382269,0.00120279,0.0002586936,0.0002138774,0.0006073812,0.000351696,0.000590577,0.002363136],"category_scores_gemma":[0.000753527,0.0001730488,0.001025653,0.0003457054,0.000327269,0.0004164336,0.00016342,0.0009950992,0.000397963],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003169272,"about_ca_system_score_gemma":0.0003209613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003227803,"about_ca_topic_score_gemma":0.001158172,"domain_scores_codex":[0.9996336,0.0001572259,0.0000314536,0.0000438364,0.00007725849,0.00005670066],"domain_scores_gemma":[0.999432,0.0001670764,0.0002205,0.00003343886,0.00005320201,0.00009365175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3911027,0.01438077,0.01727792,0.01069194,0.006448611,0.0003259657,0.0004380121,0.001244364,0.1047425,0.0003448378,0.005013326,0.447989],"study_design_scores_gemma":[0.3552352,0.4079369,0.1832195,0.001414564,0.004962155,0.001462547,0.0003697411,0.001183747,0.02375536,0.0005545961,0.01982631,0.00007947216],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.946139,0.04976365,0.0005118164,0.0004908271,0.00009791896,0.0004626483,0.0006038446,0.0001166586,0.001813598],"genre_scores_gemma":[0.9838778,0.01284203,0.0007990089,0.0006057244,0.0001211236,0.0003499304,0.0005063565,0.00002049895,0.0008774049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002363136,"threshold_uncertainty_score":0.007905483,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07613190494484223,"score_gpt":0.3808470611294208,"score_spread":0.3047151561845786,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}